File(s) not publicly available
Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia
journal contribution
posted on 2023-06-08, 16:22 authored by Inma Jarrin, Nikos Pantazis, M John Gill, Ronald Geskus, Santiago Perez-Hoyos, Laurence Meyer, Maria Prins, Giota Touloumi, Anne Johnson, Osamah Hamouda, Patricia García de Olalla, Kholoud Porter, Julia del Amo, Martin Fisher, The CASCADE Collaboration in EuroCoordBACKGROUND We examined differences by geographical origin (GO) in time from HIV seroconversion (SC) to AIDS, death, and initiation of antiretroviral therapy (cART). METHODS Data from HIV seroconverter cohorts in Europe, Australia and Canada (CASCADE) was used; GO was classified as: western countries (WE), North Africa and Middle East (NAME), sub-Saharan Africa (SSA), Latin America (LA), and Asia (ASIA). Differences by GO were assessed using Cox models. Administrative censoring date was 30 June 2008. RESULTS Of 16?941 seroconverters, 15?548 were from WE, 158 NAME, 762 SSA, 349 LA, and 124 ASIA. We found no differences by GO in risks of AIDS (P?=?.99) and death (P?=?.12), although seroconverters from NAME (adjusted hazard ratio [aHR]: 0.57; 95% CI: 0.33-.94) and SSA (aHR: 0.74; 95% CI: 0.50-1.10) appeared to have lower mortality than WE. Chances of initiating cART differed by GO (P?
History
Publication status
- Published
Journal
Clinical Infectious DiseasesISSN
1058-4838Publisher
Oxford University PressExternal DOI
Issue
1Volume
54Page range
111-118Department affiliated with
- BSMS Publications
Notes
Martin Fisher is part of the CASCADE Collaboration in EuroCoord, but is not a named author on the article.Full text available
- No
Peer reviewed?
- Yes
Legacy Posted Date
2013-12-13Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC